Acute and chronic studies of an oligomeric derivative of 1,10-bis-(2-hydroxyethylthio)-decane

A. Roda, P. Simoni, B. Grigolo, G. Scapini, V. Tumiatti, N. Ghedini

Research output: Contribution to journalArticle

Abstract

A new oligomeric derivative of thiadenol (TAD), in which the active principle is polyesterified with a bicarboxylic acid, has been studied as new retard-release prodrug (TAD-235). The compound has been acutely administered to rats and humans in order to assess, after oral administration, the dose-response serum levels of released TAD by means of a specific and sensitive enzyme immunoassay. The serum levels have been compared with those obtained by administration of TAD at equimolar dose. The results suggest an optimal bioavailability of the drug without high serum levels which, on the contrary, are constant over at least a 20-hour period. Finally, the prodrug TAD-235 was administered chronically to humans at a single daily dose of 500 mg/day, corresponding to 400 mg/day of active principle, which is five to six times lower than the dose of TAD currently used in the treatment of hyperlipidemic patients. A significant reduction of cholesterol and triglyceride levels has been observed after one month of treatment, suggesting the potential usefulness of TAD-235 as new hypolipidemic drug.

Original languageEnglish
Pages (from-to)839-845
Number of pages7
JournalCurrent Therapeutic Research
Volume42
Issue number5
Publication statusPublished - 1987

Fingerprint

Prodrugs
Serum
Hypolipidemic Agents
tiadenol
Immunoenzyme Techniques
Biological Availability
Oral Administration
Triglycerides
Cholesterol
Acids
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Roda, A., Simoni, P., Grigolo, B., Scapini, G., Tumiatti, V., & Ghedini, N. (1987). Acute and chronic studies of an oligomeric derivative of 1,10-bis-(2-hydroxyethylthio)-decane. Current Therapeutic Research, 42(5), 839-845.

Acute and chronic studies of an oligomeric derivative of 1,10-bis-(2-hydroxyethylthio)-decane. / Roda, A.; Simoni, P.; Grigolo, B.; Scapini, G.; Tumiatti, V.; Ghedini, N.

In: Current Therapeutic Research, Vol. 42, No. 5, 1987, p. 839-845.

Research output: Contribution to journalArticle

Roda, A, Simoni, P, Grigolo, B, Scapini, G, Tumiatti, V & Ghedini, N 1987, 'Acute and chronic studies of an oligomeric derivative of 1,10-bis-(2-hydroxyethylthio)-decane', Current Therapeutic Research, vol. 42, no. 5, pp. 839-845.
Roda, A. ; Simoni, P. ; Grigolo, B. ; Scapini, G. ; Tumiatti, V. ; Ghedini, N. / Acute and chronic studies of an oligomeric derivative of 1,10-bis-(2-hydroxyethylthio)-decane. In: Current Therapeutic Research. 1987 ; Vol. 42, No. 5. pp. 839-845.
@article{4707e0ee43ac4c68bb518a4b4eade76f,
title = "Acute and chronic studies of an oligomeric derivative of 1,10-bis-(2-hydroxyethylthio)-decane",
abstract = "A new oligomeric derivative of thiadenol (TAD), in which the active principle is polyesterified with a bicarboxylic acid, has been studied as new retard-release prodrug (TAD-235). The compound has been acutely administered to rats and humans in order to assess, after oral administration, the dose-response serum levels of released TAD by means of a specific and sensitive enzyme immunoassay. The serum levels have been compared with those obtained by administration of TAD at equimolar dose. The results suggest an optimal bioavailability of the drug without high serum levels which, on the contrary, are constant over at least a 20-hour period. Finally, the prodrug TAD-235 was administered chronically to humans at a single daily dose of 500 mg/day, corresponding to 400 mg/day of active principle, which is five to six times lower than the dose of TAD currently used in the treatment of hyperlipidemic patients. A significant reduction of cholesterol and triglyceride levels has been observed after one month of treatment, suggesting the potential usefulness of TAD-235 as new hypolipidemic drug.",
author = "A. Roda and P. Simoni and B. Grigolo and G. Scapini and V. Tumiatti and N. Ghedini",
year = "1987",
language = "English",
volume = "42",
pages = "839--845",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "5",

}

TY - JOUR

T1 - Acute and chronic studies of an oligomeric derivative of 1,10-bis-(2-hydroxyethylthio)-decane

AU - Roda, A.

AU - Simoni, P.

AU - Grigolo, B.

AU - Scapini, G.

AU - Tumiatti, V.

AU - Ghedini, N.

PY - 1987

Y1 - 1987

N2 - A new oligomeric derivative of thiadenol (TAD), in which the active principle is polyesterified with a bicarboxylic acid, has been studied as new retard-release prodrug (TAD-235). The compound has been acutely administered to rats and humans in order to assess, after oral administration, the dose-response serum levels of released TAD by means of a specific and sensitive enzyme immunoassay. The serum levels have been compared with those obtained by administration of TAD at equimolar dose. The results suggest an optimal bioavailability of the drug without high serum levels which, on the contrary, are constant over at least a 20-hour period. Finally, the prodrug TAD-235 was administered chronically to humans at a single daily dose of 500 mg/day, corresponding to 400 mg/day of active principle, which is five to six times lower than the dose of TAD currently used in the treatment of hyperlipidemic patients. A significant reduction of cholesterol and triglyceride levels has been observed after one month of treatment, suggesting the potential usefulness of TAD-235 as new hypolipidemic drug.

AB - A new oligomeric derivative of thiadenol (TAD), in which the active principle is polyesterified with a bicarboxylic acid, has been studied as new retard-release prodrug (TAD-235). The compound has been acutely administered to rats and humans in order to assess, after oral administration, the dose-response serum levels of released TAD by means of a specific and sensitive enzyme immunoassay. The serum levels have been compared with those obtained by administration of TAD at equimolar dose. The results suggest an optimal bioavailability of the drug without high serum levels which, on the contrary, are constant over at least a 20-hour period. Finally, the prodrug TAD-235 was administered chronically to humans at a single daily dose of 500 mg/day, corresponding to 400 mg/day of active principle, which is five to six times lower than the dose of TAD currently used in the treatment of hyperlipidemic patients. A significant reduction of cholesterol and triglyceride levels has been observed after one month of treatment, suggesting the potential usefulness of TAD-235 as new hypolipidemic drug.

UR - http://www.scopus.com/inward/record.url?scp=0023485267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023485267&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0023485267

VL - 42

SP - 839

EP - 845

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 5

ER -